<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087632</url>
  </required_header>
  <id_info>
    <org_study_id>ARMP-09</org_study_id>
    <nct_id>NCT01087632</nct_id>
  </id_info>
  <brief_title>Armolipid Plus and Metabolic Syndrome</brief_title>
  <official_title>Effects of Armolipid Plus on Indices of Insulin Resistance in Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rottapharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome is a highly prevalent condition characterized by visceral obesity,
      abnormalities of glucidic and lipid metabolism, and increased risk for cardiovascular events.
      Such findings appear to be associated with a decrease in insulin sensitivity. Management of
      metabolic syndrome is currently aimed at treating individual components of the disease
      without addressing this underlying pathophysiologic mechanism; this translates into multidrug
      regimens, high costs and patient compliance issues.

      Armolipid Plus (an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin
      K,policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg) has been found to
      be effective at reducing blood cholesterol and triglycerides, and at improving endothelial
      function; subgroup analyses also suggested a benefit on indices of insulin resistance.

      Aim of the study is to evaluate the effects of Armolipid Plus on insulin sensitivity and on
      the diagnostic parameters of metabolic syndrome.

      60 patients will be enrolled in this randomized, double-blind, placebo-controlled trial;
      active treatment will consist of Armolipid Plus (1 tbl qd).

      Primary end point will be the reduction of the insulin/glucose ratio, both after overnight
      fast (HOMA index) and after an oral glucose tolerance test (OGTT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin/glucose ratio after overnight fast</measure>
    <time_frame>18 weeks</time_frame>
    <description>HOMA INDEX</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insuline/glucose ratio after an oralglucose tolerance test</measure>
    <time_frame>18 weeks</time_frame>
    <description>OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>18 weeks</time_frame>
    <description>evaluation of weight and BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemia</measure>
    <time_frame>18 weeks</time_frame>
    <description>Blood Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>18 weeks</time_frame>
    <description>endothelial function assessed by Flow Mediated Dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein.</measure>
    <time_frame>18 weeks</time_frame>
    <description>dosage of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipidemia</measure>
    <time_frame>18 weeks</time_frame>
    <description>measure of TG and cholesterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching Armolipid plus</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Armolipid Plus</intervention_name>
    <description>Armolipid Plus 1 tablet QD for 18 weeks</description>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>berberine</other_name>
    <other_name>red yeast rice</other_name>
    <other_name>monacolin K</other_name>
    <other_name>policosanol</other_name>
    <other_name>coenzyme Q10</other_name>
    <other_name>astaxanthin</other_name>
    <other_name>folic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and Female 18-65 aged, with diagnosis of metabolic syndrome, defined by the presence
        of waist circumference &gt; 102 cm (M) or &gt;88 cm(F), and two or more of these criteria:

          -  fasting blood glucose &gt;100 mg;

          -  systolic blood pressure &gt;135 or diastolic blood pressure &gt;85 mmHg or patients in
             treatment with antihypertensive drugs;

          -  triglyceridemia &gt;150 mg/dl;

          -  HDL cholesterolemia &lt; 40 mg/dl(M), &lt; 50 mg/dl(F).

        Exclusion Criteria:

          -  pregnancy

          -  diabetes mellitus in pharmacologic treatment;

          -  hepatic failure;

          -  creatininemia &gt;2 mg/dl;

          -  triglyceridemia &gt; 500 mg/dl;

          -  heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serafino Fazio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federico II University - Department of Internal Medicine</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Massimo D'Amato, MD</name_title>
    <organization>Rottapharm</organization>
  </responsible_party>
  <keyword>Metabolic Syndrome Insulin-resistance Endothelial Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Red yeast rice</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
    <mesh_term>Policosanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

